1 for each dose vs placebo group comparison in
post hoc analysis).
2 roup (P = .002 for treatment difference in a
post hoc analysis).
3 t tests and analysis of variance with Tukey
post hoc analysis.
4 s intermediate between the two groups in the
post hoc analysis.
5 lected dermatological data were subjected to
post hoc analysis.
6 n preventing moderate to severe relapse in a
post hoc analysis.
7 h specificity (87%) and sensitivity (78%) in
post hoc analysis.
8 ACITY 006, and ASCEND) were included in this
post-hoc analysis.
9 o- or hyper-methylated locus without further
post-hoc analysis.
10 In a
post hoc analysis,
192/885 (22%) children developed dela
11 In a
post hoc analysis,
a cut-off value of CFT for systemic t
12 In addition, from
post hoc analysis,
a greater proportion of brolucizumab-
13 In a
post hoc analysis,
a rapid and transient increase in vir
14 We did a
post-hoc analysis after complete ICS withdrawal (months
15 In this
post hoc analysis,
all term white or black children with
16 In a
post hoc analysis,
an approximately 4-fold difference wa
17 Although this study was a
post hoc analysis and statistically nonsignificant, this
18 In
post-hoc analysis,
anterior AMI patients reperfused <6 h
19 Post hoc analysis assessed baseline demographics, diseas
20 The present
post hoc analysis assessed the end point of all-cause mo
21 Post hoc analysis,
between-study differences in patient
22 Post hoc analysis by age group showed improved survival
23 nd confidence intervals can be extracted and
post hoc analysis can be carried out while maintaining s
24 In this
post-hoc analysis,
Cap-assisted colonoscopy is a safe te
25 In
post hoc analysis,
clinic visits significantly increased
26 In a
post hoc analysis,
combination therapy resulted in a hig
27 DESIGN, SETTING, AND PATIENTS:
Post-hoc analysis combining raw data from 4 prospective
28 Post hoc analysis compared the 24-hour IOP pattern of th
29 The
post hoc analysis confirmed these results and also showe
30 Post hoc analysis demonstrated 8% lower FA in the left s
31 In the abatacept group,
post hoc analysis demonstrated further inhibition of rad
32 This
post hoc analysis demonstrated greater potassium and cre
33 Post hoc analysis did not detect any significant differe
34 ivariate analysis of variance (MANOVA), with
post hoc analysis employing ANOVA and paired t-tests.
35 This
post hoc analysis evaluated 3 patient groups from ATTAIN
36 This
post hoc analysis evaluated the influence of select base
37 This
post hoc analysis examined potential interaction between
38 This
post hoc analysis examined whether the effects of the SB
39 In this
post hoc analysis,
exenatide treatment was associated wi
40 A
post hoc analysis exploring the effect of atrophy in the
41 by using a one-way analysis of variance with
post hoc analysis for statistically significant differen
42 A
post hoc analysis for the primary end point considering
43 e interval: 1.02-5.24; P = .045), based on a
post-hoc analysis for the modified definition.
44 On
post hoc analysis,
for 2-year survivors, the addition of
45 In a
post hoc analysis from 10 ODYSSEY trials, greater percen
46 Post hoc analysis from a phase III randomized controlled
47 A
post hoc analysis from the Best Add-On Giving Effective
48 This is
post hoc analysis from the Clopidogrel for High Atheroth
49 N, SETTING, AND PARTICIPANTS: Retrospective,
post hoc analysis from the Efficacy of Vasopressin Antag
50 The aim of this
post hoc analysis from the TNT (Treating to New Targets)
51 d vaccine in young women, were combined in a
post-hoc analysis (
GlaxoSmithKline [GSK] e-track number
52 r systolic dysfunction were examined in this
post hoc analysis; &
gt;96% were taking BB at enrollment.
53 In a
post hoc analysis,
higher rates of HIV-1 protection were
54 hospital admission for heart failure in the
post hoc analysis (
HR 1.00, 95% CI 0.82-1.21) and result
55 Post hoc analysis identified a trend toward a greater in
56 cal P = .001 in the bilateral parietal WM; a
post hoc analysis identified growth rate differences onl
57 Here, in a
post hoc analysis in 1147 patients with type 2 diabetes
58 However, a
post hoc analysis in 30 participants with severe vitamin
59 usion in HGPIN for PCa was interrogated as a
post hoc analysis in the context of a randomized clinica
60 To this end, we performed a
post hoc analysis in the Reduction of Endpoints in NIDDM
61 We also performed a
post hoc analysis in which the rates of major complicati
62 We performed a
post-hoc analysis in 2,193 men and women with SIHD from
63 This
post-hoc analysis included 1,030 participants in the Ger
64 When RT-ungated CMR is combined with
post hoc analysis incorporating compensation for respira
65 A
post hoc analysis (
LOCF/BOCF hybrid) demonstrated a sign
66 However, in a
post hoc analysis,
losartan was associated with improved
67 In a
post-hoc analysis,
mean reductions in LDL cholesterol in
68 ed; poor mental health) were examined in the
post-hoc analysis (
n = 74, 34 CBT and 40 controls), CBT
69 view is meant to allow readers to appreciate
post hoc analysis not as an entity with a single approac
70 Post hoc analysis of (68)Ga-PSMA-11 PET/CT implied a maj
71 evidence from 1 RCT of 21 162 patients and a
post hoc analysis of 1 RCT of 15 603 patients to answer:
72 In a
post hoc analysis of 10 arm B patients with progressive
73 This was a
post hoc analysis of 130 prospectively included patients
74 nd hyperglycemia in 30 536 AMI patients in a
post hoc analysis of 2 large trials of glucose-insulin-p
75 Post hoc analysis of 2 prospectively followed up pediatr
76 We undertook a
post hoc analysis of 2 randomized clinical trials evalua
77 Post hoc analysis of 2 similarly designed phase 3 trials
78 DESIGN, SETTING, AND PATIENTS:
Post hoc analysis of 38,462 participants with hypertensi
79 This
post hoc analysis of a clinical trial assessed the medic
80 This investigation was a
post hoc analysis of a cohort in the e-ROP Study (a mult
81 We performed a
post hoc analysis of a double-blind trial comparing fond
82 In this
post hoc analysis of a large placebo-controlled randomiz
83 In this
post hoc analysis of a large, open-label, multicenter st
84 We performed a
post hoc analysis of a phase III placebo-controlled stud
85 tion on the outcome of 30-day mortality in a
post hoc analysis of a prospective cohort study of patie
86 We performed a
post hoc analysis of a published prospective multicenter
87 In this
post hoc analysis of a randomized clinical trial which t
88 We performed a
post hoc analysis of a randomized controlled trial of no
89 ed for treatment of endovascular stroke in a
post hoc analysis of a recent randomized controlled tria
90 , and Participants: This investigation was a
post hoc analysis of a subgroup of laser control eyes in
91 This investigation was a
post hoc analysis of a subgroup of laser control eyes in
92 This was a
post hoc analysis of an intention-to-treat population of
93 A meta-analysis and a
post hoc analysis of an RCT in patients with stable card
94 In a
post hoc analysis of atopic eosinophilic subjects with u
95 Post hoc analysis of cell counts rostral to the ipsilate
96 In a
post hoc analysis of children weighing 65 kg or less, th
97 Post hoc analysis of clinical and laboratory features co
98 A
post hoc analysis of clinical trials of adults with acti
99 l Coherence Tomography, seems to emerge from
post hoc analysis of collected data demonstrating strong
100 This study is a
post hoc analysis of data collected during previously pu
101 om and medication score (TCS) was based on a
post hoc analysis of data collected over six trials and
102 We performed a
post hoc analysis of data from a phase 2 trial to assess
103 In a
post hoc analysis of data from a phase III study of the
104 ional review board approval was obtained for
post hoc analysis of data from a prospective single-cent
105 We conducted a
post hoc analysis of data from pilot D-Health, which is
106 Post hoc analysis of data from the 36-month prospective,
107 Post hoc analysis of data from the inception cohort asse
108 In this
post hoc analysis of data from the Physical Activity and
109 A
post hoc analysis of data from two studies was performed
110 gle value for its corresponding gene and for
post hoc analysis of discordant groups.
111 Post hoc analysis of efficacy, safety, and resource util
112 Post hoc analysis of gene array data demonstrated signif
113 Conclusion: This
post hoc analysis of HCV patients treated with PEG-IFN a
114 We conducted a
post hoc analysis of HF-related MACE (HF hospitalization
115 Furthermore,
post hoc analysis of human class 1 papillary renal cell
116 This is a
post hoc analysis of hypertensive patients with CAD.
117 A
post hoc analysis of loci significantly associated with
118 A
post hoc analysis of Medicare Part D data revealed low p
119 An exploratory
post hoc analysis of participants with a consistent rate
120 This is a
post hoc analysis of patients enrolled in the Rituximab
121 In a
post hoc analysis of patients who also received alteplas
122 In a
post hoc analysis of patients with an initially abnormal
123 The authors performed a
post hoc analysis of patients with bloodstream infection
124 In a
post hoc analysis of patients with moderate negative sym
125 We performed a
post hoc analysis of patients with PA bloodstream infect
126 A
post hoc analysis of patients with pulseless electrical
127 In an exploratory
post hoc analysis of PFS in patients (n = 158 per arm) w
128 We therefore performed a
post hoc analysis of pooled data from six randomized, do
129 A
post hoc analysis of pooled intent-to-treat data from th
130 Post hoc analysis of prospectively collected data.
131 A
post hoc analysis of relapse, defined as a Crohn's Disea
132 In this
post hoc analysis of ROSE AHF, the response to vasoactiv
133 In a
post hoc analysis of subjects with an estimated glomerul
134 or BITA grafts and outcomes by performing a
post hoc analysis of the ART.
135 We performed a
post hoc analysis of the Assessment of Dual Antiplatelet
136 DESIGN, SETTING, AND PATIENTS:
Post hoc analysis of the Assessment of Pexelizumab in Ac
137 We performed a
post hoc analysis of the Clopidogrel After Surgery for C
138 We performed a
post hoc analysis of the Clopidogrel for the Reduction o
139 In a
post hoc analysis of the Community-Acquired Pneumonia (C
140 In this
post hoc analysis of the DEFUSE 2 study, 35 patients wit
141 CKD progression in children, we performed a
post hoc analysis of the Effect of Strict Blood Pressure
142 We performed a
post hoc analysis of the Efficacy of Vasopressin Antagon
143 We conducted a
post hoc analysis of the first and second Ramipril Effic
144 We conducted a
post hoc analysis of the Folic Acid for Vascular Outcome
145 This
post hoc analysis of the Folic Acid for Vascular Outcome
146 We performed a
post hoc analysis of the Folic Acid for Vascular Outcome
147 This secondary
post hoc analysis of the MAGIC trial included participan
148 nostic factor for overall survival (OS) in a
post hoc analysis of the Mainsail trial.
149 We performed a
post hoc analysis of the MESA (Multi-Ethnic Study of Ath
150 We performed a
post hoc analysis of the METOCARD-CNIC (effect of METOpr
151 Post hoc analysis of the multicenter TTM-trial.
152 unication in advanced cancer, we conducted a
post hoc analysis of the patient intervention component,
153 This is a
post hoc analysis of the PermiT (Permissive Underfeeding
154 Moreover, a
post hoc analysis of the phase 2 trial of NP001 using th
155 Post hoc analysis of the phase 2b Step study evaluating
156 A
post hoc analysis of the phase III PATRICIA (PApilloma T
157 Post hoc analysis of the phase III RIDE and RISE studies
158 mary prevention of atrial fibrillation, this
post hoc analysis of the PREDIMED trial suggests that ex
159 This is a
post hoc analysis of the PROTECT (Placebo-Controlled Ran
160 This is a
post hoc analysis of the RE-LY trial.
161 uncontrolled retrospective case series and a
post hoc analysis of the registration trial for temozolo
162 ion and subsequent outcomes in patients in a
post hoc analysis of the ROCKET AF (Efficacy and Safety
163 This is a
post hoc analysis of the Second Medicine, Angioplasty, o
164 Cross-sectional
post hoc analysis of the Singapore Epidemiology of Eye D
165 In this
post hoc analysis of the Singapore Epidemiology of Eye D
166 Conclusion This
post hoc analysis of the single-center SIESTA trial reve
167 Post hoc analysis of the spikes evoked by the stimulatio
168 Our
post hoc analysis of the Treating to New Targets (TNT) s
169 weight and follow-up visits and performed a
post hoc analysis of the Treating to New Targets trial,
170 A
post hoc analysis of the VISUAL-1 and VISUAL-2 placebo-c
171 In a
post hoc analysis of this dominant subgroup, 6-week mort
172 We report a
post hoc analysis of this trial after a median follow-up
173 We here report a
post hoc analysis of this trial after a median follow-up
174 The
post hoc analysis of time-specific measurements sheds li
175 Post-hoc analysis of a prospective clinical study.
176 In a
post-hoc analysis of a prospective study, EPAGE criteria
177 In this
post-hoc analysis of a randomized, double blind, placebo
178 Post-hoc analysis of all CYD14/15 trial participants rev
179 In a
post-hoc analysis of continuous electrocardiograms, most
180 We performed a
post-hoc analysis of data from a phase III, double-blind
181 on this composite outcome measure by doing a
post-hoc analysis of data from the CLARITY study.
182 We undertook a
post-hoc analysis of data from the ROCKET AF (Rivaroxaba
183 A
post-hoc analysis of data from trial of patients with NA
184 A combined
post-hoc analysis of data from two prospective, randomiz
185 We did a
post-hoc analysis of data from two replicate, randomised
186 We did a
post-hoc analysis of data, which was completed on Sept 2
187 ty to detect putative mutant phenotypes from
post-hoc analysis of large data sets.
188 r such an association exists, we undertook a
post-hoc analysis of lung cancers diagnosed in the trial
189 ied subgroup analysis in August, 2013, and a
post-hoc analysis of non-inferiority and safety in March
190 In our
post-hoc analysis of pain, brief pain inventory scores i
191 Post-hoc analysis of survival to combined endpoint in SM
192 We did a
post-hoc analysis of the 3 year inhaled Steroid Treatmen
193 This was a
post-hoc analysis of the CAPRIE (Clopidogrel Versus Aspi
194 In a
post-hoc analysis of the CAPRIE population, current smok
195 Post-hoc analysis of the estrogen plus progestin compone
196 In this
post-hoc analysis of the modified intention-to-treat pop
197 In a
post-hoc analysis of the PARADIGM-HF trial, we included
198 However, in a
post-hoc analysis of the primary endpoint, the within-tr
199 However,
post-hoc analysis of the subgroup of patients not using
200 We did a
post-hoc analysis of the trial's data to investigate beh
201 This is a retrospective
post-hoc analysis of the YELLOW II trial, comparing pati
202 Post-hoc analysis of two phase III clinical studies foun
203 Secondary
post hoc analysis outcomes included the need for renal r
204 In a
post-hoc analysis,
participants allocated to rosuvastati
205 In this
post hoc analysis,
patients with a GRACE score >140 were
206 In
post hoc analysis,
patients with low mycophenolic acid e
207 In this
post-hoc analysis,
patients with SIHD continued to exper
208 In a
post-hoc analysis,
rates of patients with inappropriate
209 In a
post-hoc analysis,
reduction of mortality was more evide
210 Post hoc analysis revealed a better survival for the PVE
211 A
post hoc analysis revealed a more complex picture where
212 Post hoc analysis revealed lower binding potential in su
213 patients with moderate negative symptoms, a
post hoc analysis revealed significant improvement of ne
214 A
post hoc analysis revealed that within the lowest-volume
215 Post hoc analysis revealed that, relative to controls, p
216 Post-hoc analysis revealed a significant increase of the
217 Post-hoc analysis revealed that the effect of DRS model
218 This
post hoc analysis reveals that treatment with denosumab
219 In
post hoc analysis,
right ventricular stroke volume incre
220 roflumilast improved lung function, and in a
post hoc analysis roflumilast significantly reduced the
221 c treatment was determined at 215.5 mum in a
post hoc analysis (
sensitivity 62.5 %, specificity 96.4
222 A
post hoc analysis showed a higher rate of relapse for pa
223 Post hoc analysis showed a low probability to reach stat
224 Post hoc analysis showed greater reductions in SLE disea
225 However, a
post hoc analysis showed that FCA increased OS in patien
226 Post hoc analysis showed that KOM had higher SBP than KO
227 Post hoc analysis showed that survival curves for GA-tre
228 Post hoc analysis showed that the combination of dnaJP1
229 A
post hoc analysis showed that this association reflected
230 Lastly,
post-hoc analysis showed a difference in the GLAST immun
231 n was 0.40 (95% CI=0.06-2.99).In contrast, a
post-hoc analysis showed that CD was associated with a s
232 Post-hoc analysis showed that patients reaching mean on-
233 Post-hoc analysis showed that the T1/2 of gastric emptyi
234 In
post-hoc analysis,
slight beneficial effects of fenofibr
235 In a
post hoc analysis,
stent length was the only subgroup of
236 The aim of the
post hoc analysis study was to evaluate the effect of ex
237 In a
post hoc analysis,
subjects who received an average dose
238 Post hoc analysis suggested that like the 22q11DS group,
239 noninferiority analysis was indeterminate, a
post hoc analysis suggested that VA improvement with thi
240 Post hoc analysis suggests GA may have slowed clinical p
241 This
post hoc analysis suggests that adalimumab is associated
242 Post hoc analysis suggests that the AA genotype of the t
243 Post hoc analysis suggests the effect of DrotAA varies b
244 However,
post-hoc analysis suggests that benefits occur in patien
245 alysis of variance procedure and appropriate
post hoc analysis techniques.
246 In a
post hoc analysis,
the 2-year cumulative incidence of he
247 In a
post hoc analysis,
the proportion of IFN-switch patients
248 In a
post hoc analysis,
the rate of major adverse cardiovascu
249 In a
post hoc analysis,
the relationship between average on-t
250 As a
post hoc analysis,
the results of this data analysis sho
251 In a
post hoc analysis,
there was evidence of a reduction in
252 In a
post hoc analysis,
there was strong evidence that solar
253 In a
post hoc analysis,
this benefit was observed only in pat
254 We conducted a
post hoc analysis to assess the effect of coadministrati
255 A
post hoc analysis to discern sources of inter-individual
256 We conducted a
post hoc analysis to explore the potential efficacy of s
257 pe prediction algorithms and high throughput
post hoc analysis to identify candidate tumor antigens.
258 CE rates, thus allowing for a (prespecified)
post hoc analysis to test associations between the chang
259 In a
post-hoc analysis to compare statins, we combined data f
260 This
post hoc analysis used data from 291 patients treated wi
261 CI, 10% to 37%) by Kaplan-Meier estimate in
post hoc analysis using definitions and methods consiste
262 treatment groups that became significant in
post hoc analysis using generalized estimating equations
263 CI, 7% to 26%) by Kaplan-Meier estimate in a
post hoc analysis using methods consistent with historic
264 In
post hoc analysis,
video laryngoscopy was associated wit
265 This exploratory
post hoc analysis was conducted between October 1, 2011,
266 was conducted from 1998 to 2006; the present
post hoc analysis was conducted from March 1, 2014, to M
267 A
post hoc analysis was conducted in women more than 2 yea
268 Post hoc analysis was conducted of prospectively collect
269 A
post hoc analysis was conducted to assess the effects of
270 Post hoc analysis was performed by a prospective multi-i
271 A
post hoc analysis was performed for delayed anemia, defi
272 A
post hoc analysis was performed of 496 patients enrolled
273 Post hoc analysis was performed of a previously conducte
274 A
post hoc analysis was performed of the Efficacy of Vasop
275 A
post hoc analysis was performed of the phase 2 trial of
276 A
post hoc analysis was performed on daily FeNO measuremen
277 A
post hoc analysis was performed to assess the impact of
278 A
post hoc analysis was performed to assess whether these
279 A
post hoc analysis was performed to determine whether uri
280 Post-hoc analysis was performed in 2,364 patients with t
281 In a
post hoc analysis we characterized clinical responders a
282 With the use of a
post hoc analysis,
we addressed the association of mater
283 In a
post hoc analysis,
we also compared results to the EFS r
284 In a
post hoc analysis,
we also compared TSPO availability be
285 In this exploratory
post hoc analysis,
we analyzed patients taking an antide
286 In a
post hoc analysis,
we compared rates of proteinuria 3 mo
287 In a
post hoc analysis,
we compared the incidence of death or
288 In this
post hoc analysis,
we investigated the relationship betw
289 In a
post hoc analysis,
we performed a cross-sectional observ
290 In a
post-hoc analysis,
we also investigated the effects on g
291 In this
post-hoc analysis,
we analysed complete clinical respons
292 In a
post-hoc analysis,
we analysed survival at 7 days after
293 In a
post-hoc analysis,
we found difference in blood pressure
294 In this
post-hoc analysis,
we test the hypothesis that the overa
295 In this
post-hoc analysis,
we used prospectively collected data
296 In this
post hoc analysis,
weight change at 12 and 24 months was
297 In a
post hoc analysis,
when patients with diabetes at baseli
298 We performed an exploratory,
post hoc analysis with 1255 participants (677 men and 57
299 Analysis of variance testing and
post hoc analysis with the Tukey test and Pearson correl
300 Post-hoc analysis with Bonferroni correction revealed th